Completed study

Official Study Title
A randomized clinical trial of oral Clarithromycin in Community-acquired pneumonia to attenuatE inflammatory responseS and improve outcomeS

Brief Description
Based on evidence coming from observational studies that addition of macrolides in the treatment regimen of community-acquired pneumonia (CAP) exhibits some anti-inflammatory mode of action, this RCT is aiming to prove that addition of oral clarithromycin to a β-lactam rapidly attenuates the high inflammatory burden of the host in CAP.

Status: Completed
Study Type: Interventional (Clinical Trial)
Study phase: III
Study sites: 26 sites in Greece
Target of enrolment: 278 participants Identifier: NCT04724044
EudraCT number: 2020-004452-15
National Organization for Medicines Approval: IS033-20
National Ethics Committee Approval: 122/20

Study Start: January 2021
Study Completion: April 2023

Condition/Disease studied: Community-acquired Pneumonia; Sepsis; Inflammatory Response; Mortality; Biomarkers; SIRS
Keywords: Macrolides; Clarithromycin

Connect to the ACCESS trial portal

Related publications